Johnson & Johnson

NYSE:JNJ   3:35:43 PM EDT
143.49
-1.75 (-1.20%)
Products, Regulatory, Earnings Announcements

Johnson And Johnson Announces European Commission Approval Of Agreement To Supply 200 Million Doses Of Janssens Covid-19 Vaccine Candidate

Published: 10/08/2020 11:58 GMT
Johnson & Johnson (JNJ) - Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's Covid-19 Vaccine Candidate.
J&j - Agreement Provides Option for European Union Member States to Secure Up to 200 Million Additional Doses for a Total of Up to 400 Million Doses.
J&j - Plans to Allocate Up to 500 Million Vaccine Doses Toward International Efforts to Ensure Access for Lower Income Countries.
J&j - Ongoing Discussions With Other Stakeholders As Part of Its Efforts to Meet Its Commitment to Make Its Covid Vaccine Candidate Accessible Globally.
J&j - Working to Further Expand Number of Available Doses of Janssen's Covid-19 Vaccine Candidate.
J&j - Second Phase 3 Study With a Two-dose Regimen is Planned to Start Later This Year.
J&j - to Date, More Than 100,000 Individuals Have Been Vaccinated With a Janssen Advac-based Vaccine.
J&j - Anticipate Covid-19 Vaccine Candidate to Be Compatible With Standard Distribution Channels Without Need for New Distribution Infrastructure.
Revenue is expected to be $21.67 Billion
Adjusted EPS is expected to be $1.84

Next Quarter Revenue Guidance is expected to be $21.65 Billion
Next Quarter EPS Guidance is expected to be $2.22

More details on our Analysts Page.